Search
Migraine Clinical Trials in Kansas City, MO
A listing of 6 Migraine clinical trials in Kansas City, MO actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 6 of 6
The city of Kansas City, Missouri, currently has 6 active clinical trials seeking participants for Migraine research studies.
Featured Trial
Child/Teen Migraine Study
Recruiting
Become part of a clinical trial today and play a role in driving medical research forward, aiding in the discovery of groundbreaking therapies. Get rewarded for your time with monetary compensation and enjoy access to medical treatment at no charge.
Featured Trial
Major Depressive Disorder Clinical Study
Recruiting
Is depression weighing you down? Local major depressive disorder clinical studies are now enrolling participants in the area. Participating in research studies helps contribute to the advancement of future medicine and treatment options. There is no obligation to take part and health insurance is not required.
Conditions:
Major Depressive Disorder
Major Depression
Major Depressive Episode
Major Depressive Disorder (MDD)
Major Depressive Disorders
Featured Trial
Migraine Clinical Trial
Recruiting
Migraine clinical trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Migraine
Migraine Disorders
Migraine Headache
Chronic Migraine
Headache
Featured Trial
Hyperacusis Activities Treatment-Online Study
Recruiting
Are you experiencing hyperacusis? If so, we are recruiting adults with hyperacusis to complete a clinical trial supported by the National Institutes of Health. The study involves participating in a remote counseling program and sound therapy trial for hyperacusis, Hyperacusis Activities Treatment-Online.
Conditions:
Hyperacusis
Tinnitus
Hearing Loss
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
Recruiting
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with chronic migraine. The study hypothesis is that in pediatric participants with chronic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
04/30/2024
Locations: Childrens Mercy Hospital and Clinics, Kansas City, Missouri
Conditions: Migraine
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
Recruiting
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with episodic migraine. The study hypothesis is that in pediatric participants with episodic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
04/30/2024
Locations: Childrens Mercy Hospital and Clinics, Kansas City, Missouri
Conditions: Migraine
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Recruiting
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
04/16/2024
Locations: Children's Mercy Hospital, Kansas City, Missouri
Conditions: Migraine
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
Recruiting
The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
04/16/2024
Locations: Children's Mercy Hospital, Kansas City, Missouri
Conditions: Episodic Migraine
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
04/15/2024
Locations: Children's Mercy Hospital, Kansas City, Missouri
Conditions: Chronic Migraine
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Recruiting
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
04/15/2024
Locations: Children's Mercy Hospital, Kansas City, Missouri
Conditions: Migraine
1 - 6 of 6